Skip to main content

ACR 2022 Tweet by Md Yuzaiful Md Yusof

View on
#ACR2022 Abstr#0003. Subgroup analysis from RECITAL RCT Rituximab vs Cyclophosphamide in CTD-ILD showed both therapies improved FVC in Myositis and MCTD but not Scleroderma. To interpret with caution (non-powered). Key message: To consider RTX as option for CTD-ILD @RheumNow
Image from Md Yuzaiful Md Yusof’s tweet
×